Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Surgical Science Sweden AB has the Financial Strength Rank of 10. It shows strong financial strength and is unlikely to fall into distressed situations.
Good Sign:
Surgical Science Sweden AB shows strong financial strength.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is rated on a scale of 1 to 10 and is based on these factors:
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.
4. Other debt related ratios.
A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.
Surgical Science Sweden AB's Interest Coverage for the quarter that ended in Mar. 2026 was 18.46.
Surgical Science Sweden AB's debt to revenue ratio for the quarter that ended in Mar. 2026 was 0.00.
As of today, Surgical Science Sweden AB's Altman Z-Score is 3.71.
Surgical Science Sweden AB (OTCPK:SUSRF) Financial Strength Explanation
The rank is rated on a scale of 1 to 10. A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.
Surgical Science Sweden AB has the Financial Strength Rank of 10. It shows strong financial strength and is unlikely to fall into distressed situations.
Surgical Science Sweden AB Financial Strength Related Terms
SUSRF vs VEEV, BTSG, HQY: Financial Strength Comparison
For the Health Information Services subindustry, Surgical Science Sweden AB's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Surgical Science Sweden AB Financial Strength vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Surgical Science Sweden AB's Financial Strength distribution charts can be found below:
* The bar in red indicates where Surgical Science Sweden AB's Financial Strength falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Surgical Science Sweden AB has enough cash to cover all of its debt. Its financial situation is stable.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Surgical Science Sweden AB has a Z-score of 3.71, indicating it is in Safe Zones. This implies the Z-Score is strong.
Good Sign:
Altman Z-score of 3.71 is strong.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Surgical Science Sweden AB (SUSRF) has a Financial Strength of 10 as of Mar. 2026. The financial strength rank measures the strength of a company's balance sheet based on revenue and debt. View historical data on Surgical Science Sweden AB and its competitors. This is near median its historical median of 10.00. Over the past decade, Surgical Science Sweden AB's Financial Strength has ranged from 7.00 to 10.00.
Is Surgical Science Sweden AB's Financial Strength too high?
Surgical Science Sweden AB's current Financial Strength of 10 is near median its 10-year median of 10.00. Over the past 10 years, this metric has ranged from a low of 7.00 to a high of 10.00. Overall, Surgical Science Sweden AB has a GF Score™ of 85/100, reflecting its overall financial health beyond just this single metric.
How does Surgical Science Sweden AB's Financial Strength compare to VEEV and BTSG?
Surgical Science Sweden AB's Financial Strength of 10 can be compared against companies in the Healthcare Providers & Services industry. Historically, Surgical Science Sweden AB's own Financial Strength has ranged from 7.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Financial Strength for a Healthcare Providers & Services company?
A good Financial Strength depends on the Healthcare Providers & Services industry context. However, Financial Strength should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Financial Strength mean?
A high Financial Strength can signal that a stock is expensive relative to its fundamentals. The financial strength rank measures the strength of a company's balance sheet based on revenue and debt. View historical data on Surgical Science Sweden AB and its competitors. Surgical Science Sweden AB's current Financial Strength is 10, which is near median its own 10-year median of 10.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Surgical Science Sweden AB stock overvalued right now?
Surgical Science Sweden AB (SUSRF) has a current Financial Strength of 10. The stock's GF Value™ is $15.91, compared to a current price of $4.00 — trading 74.9% below its estimated fair value. The current Financial Strength is 10, which is near median its 10-year median of 10.00. Surgical Science Sweden AB's overall GF Score™ is 85/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Financial Strength calculated?
Financial Strength is calculated from a company's financial statements. For Surgical Science Sweden AB (SUSRF), the current Financial Strength is 10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Surgical Science Sweden AB (SUSRF) Overvalued in 2026?
Based on GuruFocus' analysis, Surgical Science Sweden AB stock appears to be undervalued.
The current stock price of $4.00 is trading 74.9% below its estimated GF Value™ of $15.91.
Key valuation signals for SUSRF:
Financial Strength: 10 (near median its 10-year median of 10.00)
GF Value™: $15.91 vs. price of $4.00 (74.9% below fair value)
No single metric tells the full story. See the SUSRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Surgical Science Sweden AB is a supplier of virtual reality simulators for medical training. The company's core is its proprietary software and hardware for simulating interactions between instruments and anatomy. It has two operating segments: Educational products include Proprietary brand medical simulator hardware and software for generic training of psycho-motor skills, instrument handling, and training for a large number of procedures and examinations prior to entering the clinical environment, as well as support and services. Industry/OEM includes simulation software for product-specific training of surgeons in robot-assisted surgery and other digitalized medical instruments, and also simulators for medical device companies.
85GF Score
Get the complete analysis for SUSRF
Financial Strength is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SUSRF has been successfully added to your 
